Abstracts tagged "autoantibodies and prognostic factors"

Abstract Number: 882 • 2019 ACR/ARP Annual Meeting
Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis
Andrew Kinloch¹, Matthew Cascino ², Jian Dai ³, Rene Bermea ¹, Kichul Ko ¹, Margaret Vesselits ⁴, Maureen Legendre ⁵, Michael Okoreeh ¹, David Markovitz ⁵, Leonard Dragone ⁶, Michael Townsend ³ and Marcus Clark ¹, ¹University of Chicago, Chicago, IL, ²Genentech, Inc., San Fransisco, CA, ³Genentech, San Fransisco, CA, ⁴University of Chicago, Chicago, ⁵University of Michigan, Ann Arbor, MI, ⁶UCSF, San Fransisco, CA
Background/Purpose: Tubulointerstitial inflammation (TII) in lupus nephritis (LN) is associated with a worse prognosis. Vimentin, a cytoplasmic antigen, is commonly targeted by in situ activated…
Abstract Number: 360 • 2014 ACR/ARHP Annual Meeting
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Gilles Boire¹, Nathalie Carrier², Artur Jose de Brum-Fernandes³, Patrick Liang⁴, Ariel Masetto⁵, Yuan Gui⁶, Mairead Murphy⁶, Walter P. Maksymowych⁷ and Anthony Marotta⁸, ¹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Rheumatology, Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine, Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, CHUS, Sherbrooke, QC, Canada, ⁵Rheumatology, CHUS, Fleurimont, QC, Canada, ⁶Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁸1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose The 14-3-3η protein has been described as a mechanistic marker that is detectable in serum during the very early stages of RA development. A…